¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"drugs, investigational"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® parenteral administration of drugs ÇÑ±Û ºñ°æ±¸Àû ¾àǰÅõ¿©
¼³¸í   
  ÀÔÀ» ÅëÇÏÁö ¾Ê´Â ´Ù¾çÇÑ ¾àǰÅõ¿© ¹æ¹ýÀ» ¸»ÇÔ. ÁÖ»ç±â¸¦ ÀÌ¿ëÇÑ´Ù.
  
  1)ÇÇÇÏÁÖ»ç: subcutaneous injection-ÇǺΠ¹ØÀ¸·Î ÁÖ»çÇϴ °Í. ´ë°³ ÆÈÀÇ Áß°£ºÎ¿¡ ÁÖ»çÇÑ´Ù.
  
  2)ÁøÇdz»ÁÖ»ç: intradermal injection-¾ã°Ô Âñ·¯¼­ ÁøÇdz»¿¡ ÁÖ»çÇÑ´Ù. ÁַΠ¾Ë·¯Áö È¯ÀÚÀÇ Ç׿ø°Ë»ç¿¡ ÀÌ¿ëÇÑ´Ù.
  
  3)±ÙÀ°³»ÁÖ»ç: intramuscular injection-À§ÆÈÀ̳ª, È¤Àº ¾ûµ¢ÀÌ ºÎÀ§¿¡ ÁÖ»çÇÑ´Ù. À̰ÍÀº ÁַΠÇǺο¡ ÀÚ±ØÀÌ ½ÉÇÑ ¾àÁ¦³ª È¤Àº ÃµÃµÈ÷ ÀÛ¿ëÇϴ ¾àÁ¦¸¦ ¸¹ÀÌ ÁÖ»çÇÒ ¶§ »ç¿ëÇÑ´Ù.
  
  4)Ç÷°üÁÖ»ç: intravenous(IV) injection-Á¤¸ÆÀ» ÅëÇØ ÁÖ»çÇÑ´Ù. ¾î´À Á¤¸ÆÀ̳ª °¡´ÉÇÏÁö¸¸, ´ë°³ ÆÈ¶ÒÀ̳ª ¹ß µîÀÇ Á¤¸ÆÀ» ÀÌ¿ëÇÑ´Ù. ºü¸¥ Ä¡·áÈ¿°ú¸¦ º¸±â À§ÇØ »ç¿ëÇÑ´Ù. À̶§ ÇǺο¡ ÀÚ±ØÀ» Áִ ¾àÁ¦À̸é, »õÁö ¾Êµµ·Ï Á¶½ÉÇØ¾ß ÇÑ´Ù.
  
  5) ¼ö¸·°­³»ÁÖ»ç: intrathecal injection-µÎ°³³ª Ã´¼ö°­³»¿¡ ÁÖ»çÇÒ ¶§ ÀÌ¿ëÇÑ´Ù.
  
  6)°­³»ÁÖ»ç: intracavitary injection-°ø°£À¸·Î µÈ ºÎÀ§¿¡ ÁÖ»çÇÑ´Ù. ¿¹¸¦ µé¾î º¹ºÎ°ø°£À̳ª Èä°­³»¿¡ ÁÖ»çÇÏ¿© »ç¿ëÇÑ´Ù.
¿µ¹® rectal administration of drugs ÇÑ±Û ¾à¹°ÀÇ °ðâÀÚÁ¾à½Ä Åõ¿©
¼³¸í   
  ÀÔÀ» ÅëÇØ ¸ÔÀº ¾à¹°Àº Èí¼öµÈ ÈÄ °£À» °ÅÃÄ º´º¯ºÎÀ§·Î ¿î¹ÝµÈ´Ù. µû¶ó¼­ °£¿¡¼­ ´ë»ç°¡ µÇ¾î ¾à¹°·Î¼­ÀÇ È¿°ú°¡ ¾ø¾îÁú °¡´É¼ºÀÌ ÀÖÀ» »Ó ¾Æ´Ï¶ó °£¿¡ µ¶¼ºÀÛ¿ëÀ» ÀÏÀ¸Å³ ¼öµµ ÀÖ´Ù. ÀÌ·¯ÇÑ ´ÜÁ¡À» º¸¿ÏÇϱâÀ§ÇØ °£À» ÅëÇÏÁö ¾Ê°í À绡¸® Èí¼öµÇ¾î º´º¯À¸·Î °¥ ¼ö Àִ ¹æÆíÀ¸·Î Á÷ÀåÁ¾àÀ» »ç¿ëÇÑ´Ù. Á÷ÀåÀÇ Á¤¸ÆÈ帧Àº °£À» °ÅÄ¡Áö ¾Ê°í Á÷Á¢ ÇÏ´ëÁ¤¸ÆÀ» ÅëÇØ ¿ì½É¹æÀ¸·Î Èê·¯µé±â ¶§¹®ÀÌ´Ù. 
¿µ¹® side effects of drugs ÇÑ±Û ¾à¹°ÀÇ ºÎÀÛ¿ë
¼³¸í   
  ¾àÀ» »ç¿ëÇÒ ¶§ ±â´ëÇϴ ȿ°ú ¿Ü¿¡ ´Ù¸¥ Àå±â¿¡¼­ ³ªÅ¸³ª´Â ¿øÄ¡ ¾Ê´Â È¿°ú¸¦ ÃÑĪÇϴ ¸»ÀÌ´Ù. ¿¹¸¦ µé¾î Ç÷¾ÐÀ» ³·Ãß±â À§ÇØ Ç×°íÇ÷¾ÐÁ¦¸¦ »ç¿ë ½Ã, Ç÷¾ÐÀÌ ¶³¾îÁö´Â µ¿½Ã¿¡ ±â°üÁöÀÇ ¼öÃàÀÌ ÀϾ´Â Çö»ó.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • IND : investigational new drug
    ½ÃÇè¿ë½Å¾à.
  • Ganglionic blocking drugs
    ½Å°æÀýÂ÷´Ü¾àÁ¦(ãêÌèï½ó´Ó¨å·ð¥)
  • antimalarial drugs
    Ç׸»¶ó¸®¾ÆÁ¦(ù÷¡­ð¥).
  • galenical preparation =crude drugs
    »ý¾à (ßæå·).
  • hydantoinlike drugs
    È÷´ÜÅäÀξç¾àÁ¦.
  • illict drugs
    ºÒ¹ý¾à¹°
  • poisoning by drugs
    ¾à¹°Áßµ¶(ËâËÑÌ¡ËÄ).
  • poisoning by drugs
    ¾à¹°Áßµ¶(å·ÚªñéÔ¸).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • investigational agent
    Ä¡·á½ÃÇè¾à(ö½èþ ãËúÐå·).
  • antimalarial drugs
    Ç׸»¶ó¸®¾ÆÁ¦(ù÷¡­ð¥).
  • drugs
    ¾à¹°(å·Úª)
  • drugs,interaction
    »óÈ£ÀÛ¿ë(ßÓû»íÂéÄ)
  • drugs,overdosage
    °ú·®(ΦÕá)
  • drugs,side effects
    ºÎÀÛ¿ë(ÜùíÂéÄ)
  • drugs,therapeutic
    Ä¡·á(Àû)(ö½ÖûîÜ)
  • galenical preparation =crude drugs
    »ý¾à (ßæå·).
  • hydantoinlike drugs
    È÷´ÜÅäÀξç¾àÁ¦.
  • illict drugs
    ºÒ¹ý¾à¹°
  • official drugs ³ª officinalis remedies
    ¾àÀü¾à(å·îðå·), °øÁ¤¾à(ÍëïÒå·).
  • poisoning by drugs
    ¾à¹°Áßµ¶(ËâËÑÌ¡ËÄ).
  • poisoning by drugs
    ¾à¹°Áßµ¶(å·ÚªñéÔ¸).
  • sulfa drugs
    ¼³ÆÄÁ¦(¡­ð¥).
  • sustained action drugs
    ÁöÈ¿¼º ¾àÁ¦(ò¥üùàõ å·ð¥).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IDDF investigational drug data form
IDE insulin-degrading enzyme; investigational device exemption
IDS iduronate sulfatase; immune deficiency state; inhibitor of DNA synthesis; integrated delivery system...
IND indomethacin; industrial medicine; investigational new drug
DMARDs Disease Modifying Anti-Rheumatic Drugs
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IDE Investigational Device Exemption
IND Investigational New Drug
IND Investigational New Drug Application
ATD Antithyroid drugs
DMARD Disease Modifying Antirheumatic Drugs
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
drugs, investigational Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (treatment ind). The main heading includes drugs under investigation in foreign countries.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
investigational new drug Status given an experimental drug after the FDA approves an application for testing it in people.
(09 Oct 1997)
investigational new drug application An application that must be submitted to a regulatory agency (the FDA in the united states) before a drug can be studied in humans. This application includes results of previous experiments; how, where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in animal studies; and how the compound is manufactured.
(12 Dec 1998)
veterinary drugs Drugs used by veterinarians in the treatment of animal diseases. The veterinarian's pharmacological armamentarium is the counterpart of drugs treating human diseases, with dosage and administration adjusted to the size, weight, disease, and idiosyncrasies of the species. In the united states most drugs are subject to federal regulations with special reference to the safety of drugs and residues in edible animal products.
(12 Dec 1998)
cytotoxic drugs <pharmacology> Anti-cancer drugs which act by killing or preventing the division of cells.
See: chemotherapy.
(13 Nov 1997)
psychotropic drugs A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquillising agents (including the antipsychotics and anti-anxiety agents).
(12 Dec 1998)
neuroleptic drugs Literally nerve seising: used of chlorpromazine like drugs. Antagonise the effects of dopamine.
Origin: Gr. Lepsis = a taking hold
(18 Nov 1997)
street drugs Drugs obtained and often manufactured illegally for the subjective effects they are said to produce. They are often distributed in urban areas, but are also available in suburban and rural areas, and tend to be grossly impure and may cause unexpected toxicity.
(12 Dec 1998)
designer drugs Drugs designed and synthesised, often for illegal street use, by modification of existing drug structures (e.g., amphetamines). Of special interest are mptp (a reverse ester of meperidine), mda (3,4-methylenedioxyamphetamine), and mdma (3,4-methylenedioxymethamphetamine). Many drugs act on the aminergic system, the physiologically active biogenic amines.
(12 Dec 1998)
drugs, chinese herbal Chinese herbal or plant extracts which are used as drugs to treat diseases or promote general well-being. The concept does not include synthesised compounds manufactured in china.
(12 Dec 1998)
drugs, essential Drugs considered essential to meet the health needs of a population as well as to control drug costs. (world health organization action programme on essential drugs, 1994, p3)
(12 Dec 1998)
drugs, generic Drugs whose drug name is not protected by a trademark. They may be manufactured by several companies.
(12 Dec 1998)
drugs, non-prescription Drugs that can be sold legally without a prescription.
(12 Dec 1998)
drugs toxic to lung <radiology> Bleomycin, methotrexate, cytoxan, amiodarone
(12 Dec 1998)
immunosuppressive drugs Drugs that block the bodys ability to fight infection or foreign substances that enter the body. A person receiving an organ transplant is given these drugs to stop the body from rejecting the new organ or tissue. Cyclosporin is a commonly used immunosuppressive drug.
(09 Oct 1997)
orphan drugs Drugs, biologicals, and medical devices (including diagnostic in vitro tests) that may be useful in common or rare diseases but which are not considered commercially viable.
Synonym: orphan drugs.
(05 Mar 2000)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Drugs, Investigational - »õâ Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.
    Synonyms : Investigational Drugs, Drugs, Investigational New, New Drugs, Investigational
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • investigational
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á